HiFiBiO raises $37.5M in series B following 2017’s management shuffle

In August 2017, the biotech appointed new members to its management, including President and CEO Liang Schweizer and Chief Operating Officer Jeff He. (Pixabay)

HiFiBiO Therapeutics has completed a $37.5 million series B funding round, with plans to advance its antibody pipeline in oncology and autoimmune research after expanding its leadership team last summer.

The financing was led by Sequoia China and LYFE Capital, with support from the biotech’s previous series A investors, VI Ventures and Nest.Bio Ventures. New investors included Legend Star Capital and Proxima Ventures, HiFiBiO said in its announcement. Both of the company’s laboratories, in Cambridge, Massachusetts, and Hangzhou, China, are located within Nest.Bio’s incubator facilities.

In August 2017, the biotech appointed new members to its management, including President and CEO Liang Schweizer, Ph.D., who previously held management roles in cancer research at Sanofi and Bristol-Myers Squibb. HiFiBiO also named Jeff He, a former executive VP at ChemPartner, as chief operating officer.


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

Two of the original founders remain in senior positions, with Colin Brenan, Ph.D., continuing to serve as chief commercial officer and former CEO Fred Dom taking on the role of chief financial officer.

The company’s drug discovery platform, CelliGO, looks to develop therapeutic antibodies and immune system modulators through single-B-cell screening, phenotyping and analysis.

“We are very excited about HiFiBiO Therapeutics’ long-term growth trajectory,” said James Zhao, founding partner at LYFE Capital, citing the company’s ability to generate a number of antibodies in diverse tumor types.

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.